These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2391795)

  • 1. [Serum rifampicin concentrations by means of different assay methods and their critical estimation].
    Nakagawa H; Tanji S; Tsuda K; Yamada S; Kishida H
    Kekkaku; 1990 May; 65(5):317-32. PubMed ID: 2391795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tuberculosis in compromised hosts].
    Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical analysis of drug interaction between rifampicin and clarithromycin which are used for treating pulmonary Mycobacterium avium complex infection].
    Taki H; Ogawa K; Nakagawa T; Kashima K; Tarumi O; Saitou Y; Yamada N; Tano M; Nikai T
    Kekkaku; 2007 Aug; 82(8):641-6. PubMed ID: 17874572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Studies on the blood level of RFP and new administration method of RFP in relation to other anti-tuberculous drugs].
    Matsumiya T; Yamato K; Ryu C
    Kekkaku; 1985 Sep; 60(9):483-94. PubMed ID: 4079215
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical evaluation on the detection of rifampicin specific IgG, IgM].
    Li LF
    Zhonghua Jie He He Hu Xi Za Zhi; 1993 Dec; 16(6):352-4, 375. PubMed ID: 8033234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum concentrations of rifampicin and isoniazid in tuberculosis.
    Seth V; Beotra A; Seth SD; Semwal OP; Kabra S; Jain Y; Mukhopadhya S
    Indian Pediatr; 1993 Sep; 30(9):1091-8. PubMed ID: 8125594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical study of suppository formulations for improved in vivo kinetics of rifampicin.
    Taki H; Ogawa K; Nikai T
    Kekkaku; 2008 Jun; 83(6):451-6. PubMed ID: 18634449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Studies on the problems of resistance to antituberculous drugs. II--1. Clinically applicable criteria of drug-resistance to rifampicin].
    Baba H
    Kekkaku; 1994 Jun; 69(6):387-96. PubMed ID: 8041057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Detection of antibody specific to rifampicin metabolite by ELISA--mechanism of sensitization by rifampicin].
    Tomonaga H
    Arerugi; 1993 Jul; 42(7):854-63. PubMed ID: 8363438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Agranulocytosis due to anti-tuberculosis drugs including isoniazid (INH) and rifampicin (RFP)--a report of four cases and review of the literature].
    Shishido Y; Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Komatsu H; Yotsumoto H
    Kekkaku; 2003 Nov; 78(11):683-9. PubMed ID: 14672045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple-dose pharmacokinetics of ofloxacin, a new broad-spectrum antimicrobial agent.
    Dagrosa EE; Verho M; Malerczyk V; de Looze S; Hajdú P; Toyodera K
    Clin Ther; 1986; 8(6):632-45. PubMed ID: 3466701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacterial pyrogens of different origin and pharmacokinetics of rifampicin.
    Lavický J; Urbanová Z; Celeda L; Rasková H; Kvĕtina J; Vanĕcek J; Krecek J
    Arzneimittelforschung; 1987 Jun; 37(6):713-6. PubMed ID: 3663270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid determination of vitamin A (retinol) and vitamin E (alpha-tocopherol) in human serum by isocratic adsorption HPLC.
    Biesalski H; Greiff H; Brodda K; Hafner G; Bässler KH
    Int J Vitam Nutr Res; 1986; 56(4):319-27. PubMed ID: 3804606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioequivalence, antibacterial activity and therapeutic outcome of a generic meropenem (Mapenem).
    Leelarasamee A; Rongrungruang Y; Trakulsomboon S; Pongpech P; Thanawattanawanich P; Jithavech P
    J Med Assoc Thai; 2008 Jul; 91(7):980-8. PubMed ID: 18839835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chemotherapy of pulmonary Mycobacterium kansasii infection].
    Mizutani S
    Kekkaku; 1996 Sep; 71(9):527-31. PubMed ID: 8914388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of rifampicin in human plasma and blood spots by high performance liquid chromatography with UV detection: a potential method for therapeutic drug monitoring.
    Allanson AL; Cotton MM; Tettey JN; Boyter AC
    J Pharm Biomed Anal; 2007 Aug; 44(4):963-9. PubMed ID: 17531423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-tuberculosis formulations.
    Pillai G; Ellard GA; Smith PJ; Fourie PB
    Int J Tuberc Lung Dis; 2001 Aug; 5(8):691-5. PubMed ID: 11495257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NTP toxicology and carcinogenesis studies of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (CAS No. 57465-28-8) in female Harlan Sprague-Dawley rats (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2006 Jan; (520):4-246. PubMed ID: 16628245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.